AI Agents Find Drug Targets With Single-Cell Evidence Are 48% More Likely to Reach Market
james_y_zou · x · 2026-09-18
As part of the Virtual Biotech system published in Science, Stanford's James Zou group shows that multi-agent AI can integrate single-cell, cell-cell communication, spatial and clinical genomics data to generate disease-mechanism insights, flagging B7-H3 as a promising lung cancer target. By analyzing large-scale clinical trial data, the agents found that drug targets supported by single-cell evidence are 48% more likely to reach market, a signal that can help the industry prioritize targets.
More from AGI Musings
- Alpha School investigation: 17 campuses on probation, Bill Ackman as shadow lead, Holmes involved — benjaminjriley · 2026-11-02
- Google's chief economist: AI will transform more jobs than it kills — gains come from redesigning workflows — danielrock · 2026-11-02
- Daniel Lemire: AI is exploding demand for boring compute, server CPUs to double — lemire · 2026-11-02
- Alignment researcher: the word "aligned" implies consistencies that don't exist — davidmanheim · 2026-11-02
- By 2035, Indian Parents Will Ask How Many Agents You Manage, Not Your Salary — theteknosaur · 2026-11-02
- Under 5% of US consumers pay for AI, yet compute demand is already forcing usage cuts — NinaDSchick · 2026-11-02